| Biomarker ID | 256 |
| PMID | 18347174 |
| Year | 2008 |
| Biomarker | TOP2A |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa (≥2 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Apoptotic DNA fragmentation and tissue homeostasis,G0 and early G1 pathway,Delta Np63 pathway,Mitotic G1-G1/S phases,Interleukin-4 regulation of apoptosis |
| Experiment | Prostate Cancer Vs Nonneoplastic Sample |
| Type of Biomarker | Diagnostic |
| Cohort | Previously acquired gene expression profiles were analyzed from 102 tumor and nonneoplastic LCM-derived samples |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TOP2A |